Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Senzime AB
SEZISenzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue's opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden. Address: Ulls vAeg 41, Uppsala, Sweden, 756 51
Analytics
Preço Alvo de Wall Street
148.39 SEKRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave SEZI
Análise de Dividendos SEZI
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos SEZI
Avaliação de ações SEZI
Relatório SEZI
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |